Efficacy of Palmitoylethanolamide, Epilobium and Calendula suppositories for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome type III
Open-label, no control groupHumansWith Epilobium and Calendula extract
This study tested palmitoylethanolamide together with Epilobium and Calendula extract. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Open-label, no control group
- Subjects
- 45 men aged 18 to 75 with chronic prostatitis or chronic pelvic pain syndrome type III at three Italian centres; all completed
- Dose used in the study
- One rectal suppository a day containing palmitoylethanolamide, Epilobium and Calendula; amounts not in the abstract
- Duration
- 1 month
- What was measured
- NIH Chronic Prostatitis Symptom Index (primary); urinary white cells, PSA, erectile function score, pain VAS, urine flow and residual volume
What the authors reported
After one month all measures improved from baseline, including the symptom index (median 18.6 at baseline), urinary white cells, PSA and pain VAS.
Limits of this study
Open label, no control group, one month, 45 men. A three-ingredient suppository. Chronic pelvic pain fluctuates and responds to attention, so a single-arm result cannot show effect. Funding not stated in the abstract.
Source
PubMed 38934521 · doi:10.4081/aiua.2024.12582
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.